PIAM, the first company on the Italian market to work in the field of hereditary metabolic diseases, has introduced innovative and technologically advanced products, devoting itself to the development of increasingly effective, practical and highly palatable formulas with a view to improve treatment compliance.
PIAM works alongside Kyowa Hakko Bio, a world leader in biotechnology and chemical synthesis, with lines of amino acids, vitamins, nucleic acids and compounds for pharmaceutical and nutritional treatments.
PIAM is a long-standing partner of Vitaflo, a company that is specialized in human nutrition for the treatment of hereditary metabolic diseases and is part of the Nestlé Health Science group.
PIAM acts as a one-stop reference point on the market, with skills in the pharmaceutical and medical food areas, offering twofold expertise with a high degree of specialisation and diverse therapeutic treatments, customised for the management of rare and niche disorders.
PIAM’s commitment never stops and it focuses on investing in research and innovation in the orphan drugs sector, a strategic market that still requires a great deal of hard work because many rare diseases are lacking in accessible and adequate treatments.
PIAM continues to work alongside the scientific community and patients, constantly seeking out the best therapeutic solutions to protect the health of all patients.